This selection is guided by Shanghai Biomedical Science and Technology Development Center, Shanghai Jing 'an Science and Technology Commission and Shanghai Daning Asset Management (Group) Co., Ltd., and initiated by Shanghai Biomedical Industry Association in cooperation with medical science and technology. There are 9 series of selection projects, including small molecule innovative drugs, antibody drugs, innovative therapies, biotechnology, medical devices, CXO, biomedical industrial parks, brokerage investment banks and financial services institutions. Through the evaluation team, the data and public information of biomedical enterprises in 20021year were standardized and comprehensively evaluated, so as to select a number of enterprises with industry innovation value in that year.
Among them, the list of innovative medical devices mainly focuses on imaging equipment, cardiovascular and cerebrovascular implants/interventions and surgical robots. Tianzhihang's deep cultivation and innovation in orthopedic surgery robots and related technologies have been widely recognized by the industry.
Since its establishment, Tianzhihang has been focusing on the independent innovation, large-scale production, professional marketing and high-quality clinical application of orthopedic surgery robots and related technologies. It is the first enterprise in China and the fifth enterprise in the world to obtain the registration license for medical robots. At the same time, the company is also a member enterprise of TOP 10 robot in China and a supporting unit of national and local joint engineering research center for medical robots.
According to the previously published third quarterly report, in the first three quarters of 2022, the R&D investment of Tianzhihang totaled 80,328,800 yuan, a year-on-year increase of 14.95%. At the same time, this part of the funds accounted for 95.33% of the revenue, which still increased by 28.65 percentage points compared with the same period last year.
With the continuous investment in R&D, Tianzhihang has established a stable and efficient collaborative innovation mechanism of Industry-University-Research medicine relying on Beijing Medical Robot Engineering Laboratory, national and local medical robot joint engineering research centers, medical robot technology innovation centers, famous universities such as Tsinghua University and Beihang University, and superior medical institutions such as beijing jishuitan hospital and PLA General Hospital. In addition, the company has undertaken a number of national and local scientific research tasks and achieved a series of research results.
Tianzhihang's core product, Tianzhihang Orthopedic Surgery Robot, can be used to assist doctors to accurately locate implants or surgical instruments, and can be widely used in spinal and traumatic orthopedic surgery, with a clinical accuracy of less than1mm. In practice, by the end of the third quarter of 2022, Tianzhihang Orthopedic Surgery Robot has completed more than 30,000 operations, and has been applied in more than 50 hospitals nationwide, and is in a leading position in China. In addition, the clinical trial of TKA total knee replacement robot has been completed and it is expected to be listed in the first half of 2023.
Want to know more financial news in real time, please pay attention to us.